Clinical Trials/Patients

resTORbio is developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases.

As part of this commitment, we sponsor and support medical research through clinical trials. The patients, healthy volunteers, families, hospitals, and clinics involved in our trials are truly our partners in advancing the scientific understanding of aging. We appreciate each individual’s participation and the contribution they make to our growing understanding of aging-related diseases.

To learn more about resTORbio’s clinical trials, please click here.

If you have questions about our clinical trials, please contact a member of the resTORbio team.

Email: clinicaltrials@resTORbio.com

CSRI (Clinically Symptomatic Respiratory Illness) Trials

Program

RTB101 Monotherapy (PROTECTOR 1)

Phase

Phase 3 Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Status

Active; no longer recruiting

Learn More

Australian New Zealand Clinical Trials

Program

RTB101 Monotherapy (PROTECTOR 2)

Phase

Phase 3

Status

Not started

Learn More

clinicaltrial.gov

CSRI (Clinically Symptomatic Respiratory Illness) Trials

Program

Phase

Status

Learn More

RTB101 Monotherapy (PROTECTOR 1)

Phase 3 Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly

Active; no longer recruiting

Australian New Zealand Clinical Trials

RTB101 Monotherapy (PROTECTOR 2)

Phase 3

Not started

clinicaltrial.gov

Parkinson's Disease Trials

Program

RTB101 and Sirolimus Alone or in Combination

Phase

Phase 1b/2a study to determine the safety, tolerability and pharmacokinetics of RTB101 and sirolimus alone or in combination in patients with Mild or Moderate Parkinson's Disease

Status

Recruiting

Learn More

Australian New Zealand Clinical Trials

Parkinson's Disease Trials

Program

Phase

Status

Learn More

RTB101 and Sirolimus Alone or in Combination

Phase 1b/2a study to determine the safety, tolerability and pharmacokinetics of RTB101 and sirolimus alone or in combination in patients with Mild or Moderate Parkinson's Disease

Recruiting

Australian New Zealand Clinical Trials

Top